Pancreatic Ductal Adenocarcinoma — Trials

Pancreatic Ductal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

414 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 208
Recruiting: 129
Ph III recruiting: 13
Growth YoY: +56.5%
Industry share: 50%
Top sponsor: Revolution Medicines, Inc.
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–50 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02498613	A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	active not recruiting	Phase 2	122	National Cancer Institute (NCI)NIH	2	Sep 25, 2026	clinicaltrials
NCT05692596	The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics	active not recruiting	—	317	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Sep 15, 2026